Wednesday, July 8, 2026

Patent intelligence · US

US 11478517

Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof

granted A61KA61K2039/5254A61K2039/5258A61K2039/543
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 8,292
Patent details — US 11478517
Jurisdiction
US
Status
granted
Grant date
Oct 25, 2022
Expiration
Oct 20, 2042
Claims
20
CPC classes
A61K, A61K2039/5254, A61K2039/5258, A61K2039/543
View on Google Patents ↗

Quick answer

US 11478517 (Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof) is held by The Board of Regents of the University of Texas System. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K2039/5254, A61K2039/5258, A61K2039/543, A61K35/76, A61K39/12

More from The Board of Regents of the University of Texas System

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 11478517?

US 11478517 (Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof) is held by The Board of Regents of the University of Texas System. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11478517?

The Board of Regents of the University of Texas System is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 11478517 expire?

Our index shows an expiration date of Oct 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.